Antipsychotic medications are not interchangeable, and the tradeoffs between efficacy, metabolic burden, movement side effects, sedation, and adherence can be huge. In this episode, we build an antipsychotic tier list and rank medications including clozapine, olanzapine, haloperidol, risperidone, lurasidone, quetiapine, aripiprazole, and more. Along the way, we connect receptor pharmacology to practical clinical pearls, including food requirements, smoking effects, prolactin, akathisia, EPS, weight gain, long-acting injectables, and clozapine monitoring. We also discuss how medication choice shifts across schizophrenia, bipolar disorder, bipolar depression, and mood symptoms.
What we cover
* The ranking method: efficacy in schizophrenia and bipolar disorder (not as an add-on) weighed against adverse effects, the idea that metabolic burden in a young patient starts a metabolic highway, and how GLP-1 medications and metformin change that calculation.
* Haloperidol in S tier for its low metabolic burden, quetiapine in C tier, and extended-release quetiapine in D tier, with the point that quetiapine acts as a sedative at low doses, a mood agent in the middle and a D2 blocker above 400 mg.
* Clozapine in S tier, olanzapine in A tier and olanzapine-samidorphan in B tier, covering the end of the REMS, restarting titration after a gap of more than 48 hours, bowel care, olanzapine's slow time to peak, and smoking as a CYP1A2 inducer.
* Risperidone and paliperidone with its long-acting injectables in A tier, aripiprazole and cariprazine in B tier, and brexpiprazole in D tier mostly because of cost, including aripiprazole as the most studied add-on in major depression.
* Lurasidone in S tier with its calorie requirement and akathisia risk, then ziprasidone in C tier, asenapine in B tier, lumateperone and xanomeline-trospium in F tier, pimavanserin in D tier, and iloperidone and perospirone as needing more experience.
* The older drugs and add-ons: chlorpromazine in D tier, loxapine and fluphenazine in C tier, perphenazine in B tier, buspirone as a possible add-on in D tier, and adding a mood stabilizer in A tier.
Clinical takeaways
* One host argues haloperidol is underused: dose it like risperidone (most patients respond below 8 mg) and consider it after a couple of failed trials when weight gain and sedation are the worry.
* Clozapine monitoring remains the standard of care even though the REMS is gone, and a gap of more than 48 hours means restarting titration. Ask about smoking and bowel movements.
* Check prolactin early when a patient on risperidone reports menstrual, libido, breast size or milk production changes, and watch for EPS at 4 mg and above.
* Add a mood stabilizer before a second antipsychotic when a schizophrenia spectrum patient shows any mood symptoms: valproate for agitation and impulsivity, lithium or lamotrigine for depression.
* Lurasidone needs about 350 calories with the dose, so it suits steady eaters and is a poor fit when appetite fluctuates with mood or psychosis.
Read the full transcript
The complete transcript of this episode is on psycho.farm: Antipsychotic Tier List: Ranking the Best and Worst Anti-psychotics.
Related episodes
* Choosing Antipsychotics in Schizophrenia: Side-Effects, Maximizing Efficacy, and Finding the Right Medication | Episode 17
* Top 10 Things to Know About Clozapine
* Mood Stabilizers for Bipolar Disorder: Lithium, Lamotrigine, Depakote & More
For education only. Not medical advice.
This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit
psychofarm.substack.com
